Skip to main content
Business Listing Info

Business profile · Health tech

ArteraAI

Personalized precision medicine powered by AI for cancer therapy

AI-powered digital pathology platform that analyzes patient data to provide personalized cancer treatment recommendations.

About

Screenshot of the ArteraAI homepage
Homepage of ArteraAI

ArteraAI develops a multimodal AI platform that combines digital pathology analysis with clinical data to personalize cancer treatment. The company offers validated AI-powered tests for prostate cancer and breast cancer that help clinicians predict patient outcomes and treatment response. ArteraAI Prostate Test provides risk stratification for early-stage prostate cancer and metastatic hormone-sensitive prostate cancer, analyzing existing tissue slides without requiring additional staining. The ArteraAI Breast Cancer Test predicts distant metastasis risk and identifies which node-negative patients may benefit from chemotherapy. The platform has received FDA De Novo authorization and is included in the NCCN Clinical Practice Guidelines in Oncology.

Features at a glance

  • Analyzes digital pathology with no additional tissue staining required
  • Rapid results within 1-2 days after specimen receipt
  • Validated across diverse populations including African American and non-African American men
  • FDA De Novo authorization for prostate cancer risk stratification
  • Insurance coverage for Medicare and many commercial plans
  • Provides 5 and 10-year distant metastasis risk for breast cancer
  • Identifies breast cancer patients who benefit from chemotherapy
  • Included in NCCN Clinical Practice Guidelines for Prostate Cancer

Pricing

Pricing model: Contact for pricing

Quick answers

How quickly can ArteraAI test results be obtained?
Results can be shared within 1-2 days after receipt of the patient's specimen by Artera's CLIA lab.
Does ArteraAI Prostate Test require additional tissue preparation?
No. The test analyzes image data from existing H&E slides with no additional staining or tissue preparation required.
What insurance coverage is available for ArteraAI tests?
The test is fully reimbursed for Medicare patients and many commercial health plans provide coverage. Financial assistance is available for patients who qualify.
What is the ArteraAI Breast Cancer Test used for?
The test provides 5- and 10-year distant metastasis risk estimates for early-stage breast cancer patients and predicts which node-negative patients 50 years or older will benefit from chemotherapy.
How is ArteraAI Prostate Test validated?
The test has been validated in dozens of large, randomized phase III clinical trials and shows consistent prognostic performance across diverse populations including African American and non-African American men.

Leave a review for ArteraAI

Reviews of ArteraAI: none yet. Be the first.

Your rating

Reviews: free. Paid reviews: not possible. See the review file

Reviews and questions · Latest info · Share this info · Your business? Claim this profile · Report outdated info

More on this profile

ArteraAI has a free listing. The owner can unlock the full profile with a paid launch for $5:

  • Founder story (locked)
  • Milestones (locked)
  • Demo video (locked)
  • Dofollow website link (locked)

Related profiles

Questions?